Who
Douglas Kerr
Head of R&D and CMO
Company insider
Files Form 4 as: Head of R&D and CMO, Dyne Therapeutics; Chief Medical Officer, Generation Bio Co.
In numbers
- Trades disclosed
- 86
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Jan 2021
- Last trade
- 20 Oct 2026
- Last filed
- 22 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Oct 2026filed 22 Oct 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 20 Oct 2026filed 22 Oct 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K1,290 at $18.88 | filing |
| 8 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K1,290 at $18.88 | filing |
| 4 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K3,745 at $24.35 | filing |
| 4 Sep 2026filed 8 Sep 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K3,745 at $24.35 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K1,556 at $26.28 | filing |
| 13 Aug 2026filed 17 Aug 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $41K1,556 at $26.28 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K887 at $18.33 | filing |
| 16 Jun 2026filed 17 Jun 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K887 at $18.33 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K1,564 at $18.36 | filing |
| 13 May 2026filed 14 May 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $29K1,564 at $18.36 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K904 at $14.90 | filing |
| 5 Mar 2026filed 6 Mar 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $13K904 at $14.90 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 5 Dec 2025filed 5 Dec 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K880 at $20.72 | filing |
| 5 Sep 2025filed 8 Sep 2025 | DYN Dyne TherapeuticsBiotechnology | SEC FORM 4 Sold | $12K873 at $13.41 | filing |
News
No headline names them, or the companies they trade most, lately.